相关实验视频
Updated: Jun 22, 2026
10:58
Application of End-to-end Anastomosis in Robotic Central Pancreatectomy
Published on: June 2, 2018
7.9K
一种新方法可以预防由脂解引起的严重的术后胰腺
Naoto Nakamura1, Kazuyuki Nagai1, Akihiro Kaneda1
1Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Journal of hepato-biliary-pancreatic sciences
|March 5, 2025
概括
这项研究开发了一种严重的手术后胰腺 (POPF) 的老鼠模型,由胰腺汁泄漏和脂解引起. 作为脂酶抑制剂的 cetilistat 有效地减少了炎症,并在这种严重的POPF模型中改善了结果.
科学领域:
- 手术研究的研究.
- 胃肠病学 胃肠病学
- 生物医学工程 生物医学工程
背景情况:
- 手术后胰腺 (POPF) 仍然是一个重要的手术并发症.
- 严重的POPF,通常与腹内脂解有关,需要进一步调查.
- 目前对POPF的预防策略有限,特别是在严重病例中.
研究的目的:
- 通过结合胰腺汁泄漏和脂解,建立一种针对严重POPF的新型大鼠模型.
- 评估脂酶抑制剂 cetilistat 作为严重POPF的预防策略的疗效.
- 评估基于聚乙烯糖醇的水凝 (PEG-HG) 配方在提供 cetilistat 的潜力.
主要方法:
- 通过使用胰腺切割和热处理脂肪的腹腔内给药,创建了一个大鼠模型.
- 老鼠接受了水溶性 cetilistat 或带着 cetilistat 装载的 PEG-HG 内.
- 进行了生物化学测试 (FFA,炎症性细胞因子),宏观/显微镜检查和生存分析.
主要成果:
- 联合的胰腺汁泄漏和脂解模型显著增加了自由脂肪酸 (FFA),炎症性细胞因子和死亡率.
- 内塞蒂利斯塔特的使用显著降低了炎症并改善了生存率.
- 添加 cetilistat 的 PEG-HG 的疗效与水溶性 cetilistat 的疗效相当,而单独使用 PEG-HG 则没有任何益处.
结论:
- 内注射水溶性 cetilistat 有效地预防严重的炎症和并发症在严重的POPF大鼠模型.
- 塞提利斯塔特的PEG-HG配方是一个有前途的药物输送系统,可用于管理严重的POPF的潜在临床应用.
相关概念视频
01:30Acute Pancreatitis II: Clinical Manifestations and Management
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...